Introduction ▼
Obsessive-compulsive disorder (OCD) is a relatively common psychological disorder with a reported lifetime prevalence of 1-3 % in the general population [1] . Currently, selective serotonin reuptake inhibitors (SRIs) and/or cognitivebehavioral therapy, particularly exposure and response prevention (ERP), are first-line medications of choice in patients with mild to moderate OCD [2, 3] . Unfortunately, SRIs usually reduce the severity of OCD symptoms by as little as 20-30 % [4] and only 40-60 % of OCD patients achieve satisfactory results [5] [6] [7] . Hence, an increasing number of studies have focused on the development of augmentative agents in the management of OCD [1] . There is a growing body of evidence indicating the probable role of inflammatory processes and immune dysregulation in the etiopathogenesis of OCD. OCD has been reported to be associated with autoimmune disorders triggered by inflammatory processes such as streptococcal infections [8] .
Along with OCD, the findings of numerous studies also suggested the role of proinflammatory cytokines in the etiopathogenesis of several neuropsychiatric disorders including schizophrenia, bipolar disorder and major depressive disorder [13] . Furthermore, investigation of the therapeutic opportunities provided by this thesis has resulted in several studies on the treatment of neuropsychiatric disorders with promising results [14, 15] . Celecoxib is a non-steroidal anti-inflammatory drug (NSAID) and selective inhibitor of cyclooxygenase-2 (COX-2), a known promoter of both inflammation and pain. COX-2 inhibitors have been proven to be beneficial in prevention of glutamate-mediated neuronal death and suppression of proinflammatory cytokines [16, 17] . Celecoxib also has the advantage of reduced gastrointestinal complications compared to other NSAIDs. Based on the currently available data, we hypothesized that the anti-inflammatory effects of celecoxib may be beneficial in the medication management of OCD. The present 10-week, doubleblind, placebo-controlled trial aimed to evaluate the safety and efficacy of adjunctive therapy with celecoxib in improving the clinical symptoms of moderate to severe OCD.
Patients and Methods

▼
Trial design and setting
A single-center, 10-week, randomized, double-blind, placebocontrolled, parallel-group trial was conducted in the outpatient clinics of Roozbeh Psychiatric Hospital (Tehran University of Medical Sciences, Tehran, Iran) from January 2014 to November 2014. Approval was obtained from the Institutional Review Board (IRB) of Tehran University of Medical Science (Grant No: 23218). The trial was performed according to the Declaration of Helsinki and its subsequent revisions. All patients signed an informed consent prior to study entry. The trial was registered at the Iranian registry of clinical trials (www.irct.ir; registration number: IRCT201312181556N56).
Participants
Men and women, aged between 18-60 years, with a diagnosis of OCD according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) and a Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score of ≥ 21 to have moderate to severe OCD, were eligible to take part in the study. Exclusion criteria were as follows: any other mental disorder on DSM-IV axis I, alcohol or substance (with the exception of nicotine) dependence, intelligence quotient < 70, any serious medical illness including cardiac, hepatic and renal disease, ingestion of any psychotropic medications during the last 6 weeks, pregnancy, breast feeding and rises in liver transaminase to 3 times the upper limit of normal or higher.
Interventions
Eligible participants were randomly assigned to receive either 200 mg celecoxib (celebrex, Pfizer, 200 mg capsule) twice daily or placebo in the same manner for 10 weeks. All patients, regardless of their treatment group, also received fluvoxamine 100 mg/ day for the first 4 weeks of the study followed by 200 mg/day for the rest of the trial course.
Outcomes
All patients were assessed using Y-BOCS at baseline and weeks 4 and 10. A psychiatrist with good experience in implementing the Y-BOCS who had been involved in several clinical trials was in charge of rating the patients. The main outcome measure of this trial was evaluation of celecoxib efficacy in improvement of Y-BOCS total score compared to placebo using the general linear repeated measure model. Partial response and complete response were defined as 25 % and 35 % reduction in the Y-BOCS score, respectively. A Y-BOCS score < 16 was considered as remission. Adverse events were systematically evaluated at each time point.
Sample size
Assuming a difference of 4 on the Y-BOCS total score between the celecoxib group and the placebo group with a standard deviation (SD) of 4.5, a power of 80 %, and a two-sided significance level of 5 %, a sample size of 42 was needed. Considering a 20 % attrition rate, a final sample size of 54 was planned.
Randomization, allocation, concealment and blinding
Generation of randomization codes was performed by a computerized random number generator (blocks of 4, allocation ratio 1:1). Concealment of allocation was performed using sequentially numbered and sealed packages. Separate people were responsible for random allocation and rating of the patients. The patients, research investigators, rater and the statistician were all blinded to the allocated treatment. Celecoxib and placebo capsules were completely identical in their shape, color, size, texture, and odor. The placebo rate anticipation was also assessed by the participants, and the rater at the study end.
Statistical analysis
All analyses were carried out according to the intention-to-treat principles with at least one post-baseline measurement. Continuous variables were reported as mean ± standard deviation (SD) and categorical variables were reported as frequency (percentage). Baseline continuous variables were compared using an independent t-test. A general linear model repeated measure was used to evaluate time × treatment interaction considering the treatment group (celecoxib vs. placebo) as the between-subject factor and the study measurements as the within-subject factor (time). Greenhouse-Geisser adjustment in degrees of freedom was made if Mauchly's test of sphericity was significant. An independent t-test and Cohen's d effect size were used to compare score change from baseline to each time interval between the 2 study groups. Categorical variables were compared using chi-square test or Fisher's exact test as appropriate. The time needed to respond to treatment was compared between the celecoxib and the placebo groups using KaplanMeier estimation with log-rank test. Statistical Package of Social Science Software (SPSS version 20, IBM Company, Armonk NY, USA) was used for statistical analysis and the graphs were drawn using SigmaPlot (version 12).
Results
▼
Participants and baseline characteristics
A total of 104 participants screened for eligibility criteria, among them 54 patients, were randomly assigned to receive either celecoxib plus fluvoxamine (n = 27) or placebo plus fluvoxamine (n = 25). 50 patients (25 in each group) had at least one postbaseline measurement and a similar number of study participants completed the trial ( • ▶ Fig. 1 ). Baseline characteristics of the patients were not significantly different between the groups ( • ▶ Fig. 2a) .
At the study conclusion, remission achieved in 15 (60 %) patients in the celecoxib group was compared with 8 (32 %) patients in the placebo group (p < 0.047). Significantly, higher partial and complete response rates were also observed in the celecoxib group than the placebo group at the end of the trial ( • ▶ Table 2 ).
An independent t-test demonstrated significantly greater reduction in Y-BOCS total score in the celecoxib group than the placebo group at weeks 4 and 10 ( • ▶ Table 3 ). Kaplan-Meier estimation showed that a shorter time was needed in the celecoxib group than the placebo group for partial response, p < 0.001. Fig. 2b ).
Y-BOCS obsession subscale score
An independent t-test demonstrated significantly greater reduction in Y-BOCS obsession subscale scores in the celecoxib group than the placebo group at weeks 4 and 10 ( • ▶ Table 3 Table 3 ).
Adverse events
Frequency of adverse events did not differ significantly between treatment groups ( • ▶ Table 4 ). No serious adverse events or deaths occurred.
Blinding
The participants and the rater were unsure about the treatment allocation in more than 50 % of the allocations.
Discussion
▼
The results of the current study showed that the administration of celecoxib, as an adjuvant agent in addition to fluvoxamine, is significantly superior to fluvoxamine monotherapy in reducing both obsessive and compulsive symptoms and achieving a more rapid response to treatment in patients with moderate to severe OCD. The use of celecoxib also appeared to be safe and well tolerated in our study population and no clinically significant adverse effect was reported. The response to treatment in the placebo arm who received monotherapy with fluvoxamine was similar to the previous reports of treatment outcome with SRIs in OCD patients [4] . Fluvoxamine monotherapy resulted in about 30 % reduction in OCD symptoms (9.4 points on Y-BOCS total score). Celecoxib plus fluvoxamine resulted in about 50 % reduc- [18] . They found that those in the celecoxib group showed a greater improvement of OCD symptoms compared to controls who received fluoxetine and placebo. The superior effect of celecoxib compared to placebo was observed as soon as 2 weeks after the initiation of therapy and was still significant at the study end at week 8. In agreement with their report, we found a significantly greater improvement of OCD symptoms in the first assessment after receiving medication for 4 weeks and the results were repeated at week 10. The beneficial effects of celecoxib in rapid reduction of obsessive and compulsive symptoms may be explained mainly by the role of COX-2 inhibitors in the suppression of inflamma- Table 4 The frequency of different types of adverse events in the study population. Table 2 Comparison of changes in the Yale-Brown Obsessive Compulsive Scale total and subscales scores from baseline between the 2 groups using independent t-test. tory processes in the brain. COX-2 plays an important role in the initiation of inflammatory processes by catalyzing the conversion of arachidonic acid to prostaglandin H2 [19] . Prostaglandin H2 itself is a precursor for other biologically active molecules involved in further regulation of inflammatory cascades including prostaglandin D2, prostaglandin E2, prostacyclin and thromboxane A2 [20] . Most recently, Konuk et al. evaluated the plasma levels of 2 proinflammatory cytokines, interleukin-6 (IL-6) and tumor necrosis factor(TNF)-α, among OCD patients with no major neuropsychological disorder who had not have received any psychotropic agents or NSAIDs for at least 3 months prior to blood sampling [21] . They reported higher plasma levels of both IL-6 and TNF-α in OCD patients compared to healthy controls. Moreover, they found a negative correlation between TNF-α level and the onset of disease as well as a weak correlation between IL-6 levels and duration of illness. The authors suggested that new therapeutic modalities can be developed based on the speculated role of inflammation in the etiopathogenesis of OCD. Nevertheless, a recent meta-analysis showed that overall plasma levels of IL-1β are reduced in OCD patients relative to controls, while there is no overall difference in TNF-α and IL-6 plasma levels [22] . Interestingly, celecoxib is known to significantly reduce elevated levels of both IL-6 and TNF-α, which further supports the importance of its anti-inflammatory characteristics in improving clinical symptoms of OCD patients [14, 15] . In the present study, celecoxib was administrated with a dosage of 200 mg twice daily with no serious adverse events. We have already reported the safety and tolerability of this practice in several previous studies [14, 15] . We did not witness any serious cardiovascular adverse effects here. Indeed, the lack of such findings can be attributed to the low doses of celecoxib administered, short duration of therapy and follow-up, and relatively small number of patients investigated. Limitations of the present study include: small sample size, short follow-up period and no assessment of proinflammatory cytokines.
Adverse event
In conclusion, the results of the current study suggest that the administration of celecoxib as an adjuvant agent with SRIs might help in achieving rapid and more satisfying improvements in OCD symptoms. Further randomized controlled trials with larger sample sizes, longer study duration, and proinflammatory cytokine assessment are warranted in order to confirm the beneficial effects of celecoxib in long-term management of OCD.
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